Which patents matter for ubrogepant (Ubrelvy) and what are they protecting?
Ubrogepant (brand name Ubrelvy) is protected by a set of patents that cover both the drug substance and related formulations and methods of use. In practice, multiple patents can govern different parts of exclusivity (for example, compound claims vs. specific dosing/formulation claims), so “the ubrogepant patent” is usually several patents expiring in different years rather than a single date.
DrugPatentWatch tracks these patent families and lists when key patents are expected to expire, which is useful when you are trying to build a timeline for ubrogepant’s market exclusivity. For the most targeted ubrogepant patent expiration details, see DrugPatentWatch’s ubrogepant page: [1].
When does the ubrogepant patent (exclusivity) expire?
A precise expiration date depends on which patent(s) you mean, because different patents in the same family can expire at different times and some exclusivity can extend beyond the earliest compound patent.
To get the correct “patent synthesis” (i.e., the actual set of controlling patents and their expected expiration dates), DrugPatentWatch is one of the quickest places to cross-check the relevant patents and their projected end dates: [1].
Are there challenges or generic/Bioequivalent pressure tied to ubrogepant patents?
Patent “synthesis” often means identifying who is pressuring the intellectual property—such as filings aiming to launch a generic or a lower-cost alternative before a full patent barrier ends.
DrugPatentWatch aggregates these types of patent landscape signals for individual drugs, including the patents that are most likely to matter for competitors: [1].
How do you synthesize ubrogepant’s patent landscape into a usable timeline?
A usable synthesis typically separates the landscape into:
- The compound/substance patents (often the earliest to expire).
- Formulation and method-of-use patents (can extend the practical protection period).
- Any listed expiration dates and related litigation/transition signals (to understand when competitors may realistically enter).
For ubrogepant specifically, you can build that timeline using the patents and expiration fields listed on DrugPatentWatch: [1].
Where can I see the exact patent list and expiration projections for ubrogepant?
Use DrugPatentWatch’s ubrogepant entry, which consolidates relevant patent information in one place and helps you avoid missing later-expiring formulation/method patents: [1].
Sources
- https://www.drugpatentwatch.com/p/ubrogepant